Kurt W. Tauer, MD, FACP, discusses the expansion of subtyping in breast cancer.
Kurt W. Tauer, MD, FACP
Advertisement
Articles by Kurt W. Tauer, MD, FACP
Kurt W. Tauer, MD, FACP, discusses the potential implications of biosimilars on cancer research funding.
Advertisement
Latest Updated Articles
Dr. Tauer on the Potential Implications of Biosimilars on Cancer Research FundingPublished: November 16th 2019 | Updated:
Dr. Tauer on the Expansion of Subtyping in Breast CancerPublished: January 17th 2020 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
2
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
3
Anti–Gremlin-1 Therapy Plus Chemo Makes Waves in GI Malignancies
4
FDA Grants Fast Track Designation to IBI3003 in Relapsed/Refractory Multiple Myeloma
5